{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:24:16Z","timestamp":1791347056861,"version":"4.3.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mutations in the uroporphyrinogen III synthase (UROS) gene cause congenital erythropoietic porphyria (CEP), an autosomal-recessive inborn error of erythroid heme biosynthesis. Clinical features of CEP include dermatologic and hematologic abnormalities of variable severity. The discovery of a new type of erythroid porphyria, X-linked dominant protoporphyria (XLDPP), which results from increased activity of 5-aminolevulinate synthase 2 (ALAS2), the rate-controlling enzyme of erythroid heme synthesis, led us to hypothesize that the CEP phenotype may be modulated by sequence variations in the ALAS2 gene. We genotyped ALAS2 in 4 unrelated CEP patients exhibiting the same C73R\/P248Q UROS genotype. The most severe of the CEP patients, a young girl, proved to be heterozygous for a novel ALAS2 mutation: c.1757 A &gt; T in exon 11. This mutation is predicted to affect the highly conserved and penultimate C-terminal amino acid of ALAS2 (Y586). The rate of 5-aminolevulinate release from Y586F was significantly increased over that of wild-type ALAS2. The contribution of the ALAS2 gain-of-function mutation to the CEP phenotype underscores the importance of modifier genes underlying CEP. We propose that ALAS2 gene mutations should be considered not only as causative of X-linked sideroblastic anemia (XLSA) and XLDPP but may also modulate gene function in other erythropoietic disorders.<\/jats:p>","DOI":"10.1182\/blood-2011-03-342873","type":"journal-article","created":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T20:24:04Z","timestamp":1307564644000},"page":"1443-1451","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":81,"title":["ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria"],"prefix":"10.1182","volume":"118","author":[{"given":"Jordi","family":"To-Figueras","sequence":"first","affiliation":[{"name":"Biochemistry and Molecular Genetics Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ducamp","sequence":"additional","affiliation":[{"name":"AP-HP, Centre Fran\u00e7ais des Porphyries, H\u00f4pital Louis Mourier, Colombes, France;"},{"name":"Inserm Unit\u00e9 773, Centre de Recherche Biom\u00e9dicale Bichat-Beaujon; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, site Bichat, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Clayton","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, College of Medicine, University of South Florida, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Badenas","sequence":"additional","affiliation":[{"name":"Biochemistry and Molecular Genetics Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain;"},{"name":"CIBERER, Instituto de Salud Carlos III, Hospital Clinic, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Delaby","sequence":"additional","affiliation":[{"name":"AP-HP, Centre Fran\u00e7ais des Porphyries, H\u00f4pital Louis Mourier, Colombes, France;"},{"name":"Inserm Unit\u00e9 773, Centre de Recherche Biom\u00e9dicale Bichat-Beaujon; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, site Bichat, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Ged","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Bordeaux and Inserm, Bioth\u00e9rapies des maladies g\u00e9n\u00e9tiques et cancers, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Lyoumi","sequence":"additional","affiliation":[{"name":"Inserm Unit\u00e9 773, Centre de Recherche Biom\u00e9dicale Bichat-Beaujon; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, site Bichat, Paris, France;"},{"name":"Universit\u00e9 de Versailles\u2013Saint Quentin en Yvelines\u2013UFR de M\u00e9decine Paris-Ile de France Ouest, Versailles, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Gouya","sequence":"additional","affiliation":[{"name":"AP-HP, Centre Fran\u00e7ais des Porphyries, H\u00f4pital Louis Mourier, Colombes, France;"},{"name":"Inserm Unit\u00e9 773, Centre de Recherche Biom\u00e9dicale Bichat-Beaujon; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, site Bichat, Paris, France;"},{"name":"Universit\u00e9 de Versailles\u2013Saint Quentin en Yvelines\u2013UFR de M\u00e9decine Paris-Ile de France Ouest, Versailles, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"de Verneuil","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Bordeaux and Inserm, Bioth\u00e9rapies des maladies g\u00e9n\u00e9tiques et cancers, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Beaumont","sequence":"additional","affiliation":[{"name":"Inserm Unit\u00e9 773, Centre de Recherche Biom\u00e9dicale Bichat-Beaujon; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, site Bichat, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria C.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, College of Medicine, University of South Florida, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Deybach","sequence":"additional","affiliation":[{"name":"AP-HP, Centre Fran\u00e7ais des Porphyries, H\u00f4pital Louis Mourier, Colombes, France;"},{"name":"Inserm Unit\u00e9 773, Centre de Recherche Biom\u00e9dicale Bichat-Beaujon; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, site Bichat, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Herrero","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Puy","sequence":"additional","affiliation":[{"name":"AP-HP, Centre Fran\u00e7ais des Porphyries, H\u00f4pital Louis Mourier, Colombes, France;"},{"name":"Inserm Unit\u00e9 773, Centre de Recherche Biom\u00e9dicale Bichat-Beaujon; Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, site Bichat, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2019111808365430600_B1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2141.2002.03557.x","article-title":"Congenital erythropoietic porphyria: advances in pathogenesis and treatment.","volume":"117","author":"Desnick","year":"2002","journal-title":"Br J Haematol"},{"issue":"9718","key":"2019111808365430600_B2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","article-title":"Porphyrias.","volume":"375","author":"Puy","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"2019111808365430600_B3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1172\/JCI10642","article-title":"Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria.","volume":"107","author":"Solis","year":"2001","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111808365430600_B4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/humu.10212","article-title":"Human Gene Mutation Database (HGMD): 2003 update.","volume":"21","author":"Stenson","year":"2003","journal-title":"Hum Mutat"},{"issue":"1","key":"2019111808365430600_B5","first-page":"53","article-title":"Congenital erythropoietic porphyria: mutation update and correlations between genotype and phenotype.","volume":"55","author":"Ged","year":"2009","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"8","key":"2019111808365430600_B6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1046\/j.1365-2230.2002.01166.x","article-title":"Congenital erythropoietic porphyria: dilemmas in present day management.","volume":"27","author":"Dawe","year":"2002","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"2019111808365430600_B7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1172\/JCI115637","article-title":"Congenital erythropoietic porphyria: identification and expression of exonic mutations in the uroporphyrinogen III synthase gene.","volume":"89","author":"Warner","year":"1992","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111808365430600_B8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1021\/bi801731q","article-title":"Uroporphyrinogen III synthase mutations related to congenital erythropoietic porphyria identify a key helix for protein stability.","volume":"48","author":"Fortian","year":"2009","journal-title":"Biochemistry"},{"issue":"3","key":"2019111808365430600_B9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/0888-7543(95)80175-L","article-title":"Uroporphyrinogen-III synthase: molecular cloning, nucleotide sequence, expression of a mouse full-length cDNA, and its localization on mouse chromosome 7.","volume":"26","author":"Xu","year":"1995","journal-title":"Genomics"},{"issue":"3","key":"2019111808365430600_B10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bcmd.2006.12.001","article-title":"Study of the genotype-phenotype relationship in four cases of congenital erythropoietic porphyria.","volume":"38","author":"To-Figueras","year":"2007","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"2019111808365430600_B11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.0022-202X.2004.23401.x","article-title":"Congenital erythropoietic porphyria: report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling.","volume":"123","author":"Ged","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2019111808365430600_B12","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ajhg.2008.08.003","article-title":"C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload.","volume":"83","author":"Whatley","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2019111808365430600_B13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0888-7543(90)90542-3","article-title":"Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome.","volume":"7","author":"Bishop","year":"1990","journal-title":"Genomics"},{"issue":"7","key":"2019111808365430600_B14","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/jcp.54.7.500","article-title":"ACP Best Practice No 165: front line tests for the investigation of suspected porphyria.","volume":"54","author":"Deacon","year":"2001","journal-title":"J Clin Pathol"},{"issue":"7","key":"2019111808365430600_B15","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/clinchem\/31.7.1163","article-title":"Rapid procedure for fecal porphyrin assay.","volume":"31","author":"Lockwood","year":"1985","journal-title":"Clin Chem"},{"issue":"1","key":"2019111808365430600_B16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0009-8981(84)90192-X","article-title":"Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias.","volume":"139","author":"Lim","year":"1984","journal-title":"Clin Chim Acta"},{"key":"2019111808365430600_B17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0378-4347(00)83869-4","article-title":"High-performance liquid chromatography of porphyrins.","volume":"429","author":"Lim","year":"1988","journal-title":"J Chromatogr"},{"issue":"3","key":"2019111808365430600_B18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0003-2697(87)90554-9","article-title":"Coupled-enzyme and direct assays for uroporphyrinogen III synthase activity in human erythrocytes and cultured lymphoblasts. Enzymatic diagnosis of heterozygotes and homozygotes with congenital erythropoietic porphyria.","volume":"166","author":"Tsai","year":"1987","journal-title":"Anal Biochem"},{"issue":"3","key":"2019111808365430600_B19","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells.","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2019111808365430600_B20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00431-006-0211-3","article-title":"Severe X-linked chronic granulomatous disease in 2 unrelated females.","volume":"166","author":"Chollet-Martin","year":"2007","journal-title":"Eur J Pediatr"},{"issue":"11","key":"2019111808365430600_B21","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1182\/blood.V84.11.3915.bloodjournal84113915","article-title":"X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley.","volume":"84","author":"Cotter","year":"1994","journal-title":"Blood"},{"issue":"1","key":"2019111808365430600_B22","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0021-9258(18)54191-0","article-title":"Expression of mammalian 5-aminolevulinate synthase in Escherichia coli. Overproduction, purification, and characterization.","volume":"268","author":"Ferreira","year":"1993","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111808365430600_B23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/humu.21455","article-title":"Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of ten missense mutations.","volume":"32","author":"Ducamp","year":"2011","journal-title":"Hum Mutat"},{"issue":"1","key":"2019111808365430600_B24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid.","volume":"150","author":"Smith","year":"1985","journal-title":"Anal Biochem"},{"issue":"2","key":"2019111808365430600_B25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/abio.1995.1217","article-title":"A continuous spectrophotometric assay for 5-aminolevulinate synthase that utilizes substrate cycling.","volume":"226","author":"Hunter","year":"1995","journal-title":"Anal Biochem"},{"issue":"10","key":"2019111808365430600_B26","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1021\/bi9719298","article-title":"Aspartate-279 in aminolevulinate synthase affects enzyme catalysis through enhancing the function of the pyridoxal 5\u2032-phosphate cofactor.","volume":"37","author":"Gong","year":"1998","journal-title":"Biochemistry"},{"issue":"18","key":"2019111808365430600_B27","doi-asserted-by":"crossref","first-page":"12222","DOI":"10.1074\/jbc.274.18.12222","article-title":"Pre-steady-state reaction of 5-aminolevulinate synthase. Evidence for a rate-determining product release.","volume":"274","author":"Hunter","year":"1999","journal-title":"J Biol Chem"},{"key":"2019111808365430600_B28","article-title":"Molecular enzymology of 5-aminolevulinate synthase, the gatekeeper of heme biosynthesis [published online ahead of print January 6, 2011].","author":"Hunter","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"2019111808365430600_B29","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1110\/ps.041258305","article-title":"Conversion of 5-aminolevulinate synthase into a more active enzyme by linking the two subunits: spectroscopic and kinetic properties.","volume":"14","author":"Zhang","year":"2005","journal-title":"Protein Sci"},{"issue":"5","key":"2019111808365430600_B30","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/pro.5560040520","article-title":"Aminolevulinate synthase: lysine 313 is not essential for binding the pyridoxal phosphate cofactor but is essential for catalysis.","volume":"4","author":"Ferreira","year":"1995","journal-title":"Protein Sci"},{"issue":"12","key":"2019111808365430600_B31","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1021\/bi982390w","article-title":"Lysine-313 of 5-aminolevulinate synthase acts as a general base during formation of the quinonoid reaction intermediates.","volume":"38","author":"Hunter","year":"1999","journal-title":"Biochemistry"},{"issue":"18","key":"2019111808365430600_B32","doi-asserted-by":"crossref","first-page":"13704","DOI":"10.1074\/jbc.M109.074237","article-title":"Targeting the active site gate to yield hyperactive variants of 5-aminolevulinate synthase.","volume":"285","author":"Lendrihas","year":"2010","journal-title":"J Biol Chem"},{"issue":"3","key":"2019111808365430600_B33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF00197267","article-title":"Heterogeneity of mutations in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria.","volume":"88","author":"Boulechfar","year":"1992","journal-title":"Hum Genet"},{"issue":"5","key":"2019111808365430600_B34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000472214","article-title":"A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria.","volume":"4","author":"Fontanellas","year":"1996","journal-title":"Eur J Hum Genet"},{"issue":"Pt 3","key":"2019111808365430600_B35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1469-1809.1998.6230225.x","article-title":"C73R is a hotspot mutation in the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria.","volume":"62","author":"Frank","year":"1998","journal-title":"Ann Hum Genet"},{"issue":"9","key":"2019111808365430600_B36","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2006-06-022848","article-title":"Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria.","volume":"109","author":"Phillips","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111808365430600_B37","first-page":"118","article-title":"The molecular genetics of erythropoietic protoporphyria.","volume":"55","author":"Elder","year":"2009","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"6","key":"2019111808365430600_B38","first-page":"533","article-title":"Gene symbol: ALAS2. disease: sideroblastic anaemia.","volume":"115","author":"Pereira","year":"2004","journal-title":"Hum Genet"},{"issue":"12","key":"2019111808365430600_B39","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1182\/blood-2002-03-0685","article-title":"Absent phenotypic expression of X-linked sideroblastic anemia in one of 2 brothers with a novel ALAS2 mutation.","volume":"100","author":"Cazzola","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111808365430600_B40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2141.1999.01479.x","article-title":"A novel mutation of the erythroid-specific delta-aminolaevulinate synthase gene in a patient with X-linked sideroblastic anaemia.","volume":"106","author":"Harigae","year":"1999","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111808365430600_B41","first-page":"56","article-title":"The molecular biology and pyridoxine responsiveness of X-linked sideroblastic anaemia.","volume":"83","author":"May","year":"1998","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/6\/1443\/1345821\/zh803211001443.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/6\/1443\/1345821\/zh803211001443.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T07:25:54Z","timestamp":1712474754000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/6\/1443\/29091\/ALAS2-acts-as-a-modifier-gene-in-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,11]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-03-342873","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,11]]}}}